Emphasis on Product (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta); Indication (Relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma); End-Users (Hospitals, Cancer Treatments Centers, and Others); Region/Country
Global CAR T-cell therapy Market is anticipated to grow with an exponential CAGR over the forecast period (2021-2027). CAR T-Cell Therapy is a type of immunotherapy that is regarded as s revolutionary therapy for cancer. In this therapy, the T-cells are taken from the patient’s blood and are modified in the laboratory for attacking the cancer cells. CAR T-cell therapy is most commonly used to treat certain blood cancers and is being studied for the treatment of other cancer types.
The growing adoption of CAR T-Cell Therapy can be attributed to the surging incidences of cancer coupled with a rapidly growing geriatric population. According to the United Nations, the 60+ aged population was 962 million in 2017 which is more than twice that it was in 1980 at 382 million. The number of elderly is expected to double again by 2050 and reach nearly 2.1 billion worldwide. Further, it has been estimated by CDC that the number of cancer cases in the US will increase 49% each year, from 1,534,500 in 2015 to 2,286,300 in 2050, with the largest percentage increase among adults aged ≥75 years. This exponential increase in cancer prevalence globally has created a buzz among various pharmaceutical companies for investing in the development of novel and effective cancer treatment. Thereby, boosting the growth of the CAR T-Cell Therapy Market.
Furthermore, the CAR T-Cell Therapy market is anticipated to grow on account of the growing technological advancement, a large number of ongoing research activities in this field, rising government and public-private investments, a huge CAR T-cell pipeline, and increasing FDA approvals. For example, in February 2022, the FDA approved carvykti, a new customized, cell-based treatment from Johnson & Johnson, for the treatment of multiple myeloma. However, some of the restraints in the market including high-touch commercial models and side-effects associated with CAR T-cell therapy are impeding the growth of this market all over the world.
Distribution of Cancer Incidence Worldwide (%), 2020, By Gender
Novartis AG, Gilead Sciences, Inc., Amgen, Inc., Juno Therapeutics, Eli Lilly and Company, Sorrento Therapeutics, Fate Therapeutics, Inc., Johnson & Johnson, Celgene Corporation, Bluebird bio, Inc., are some of the prominent players operating in the CAR T-cell therapy market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with CAR T-cell therapy.
Insights Presented in the Report
“Amongst Product, yescarta segment holds the major share”
Based on product, the CAR T-Cell Therapy market is segmented into abecma, breyanzi, Kymriah, tecartus, and yescarta. The yescarta segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe. Yescarta is the first CAR T-cell therapy that has been approved for certain types of non-Hodgkin lymphoma (NHL). The growth of this segment can be attributed to the customization of each dose of yescarta as the treatment is created by using a patient’s immune system to help fight the lymphoma.
“Amongst Indication, relapsed Large B-cell Lymphoma segment holds the major share”
Based on indication, the CAR T-Cell Therapy market is divided into relapsed Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL), and Multiple Myeloma. The relapsed Large B-cell Lymphoma segment occupied the major share of the CAR T-Cell Therapy market in 2020 and it is expected to grow with a substantial CAGR in the upcoming years. The growth of this segment is attributed to the growing incidences of relapsed large b-cell lymphoma and the increase in FDA approval of CAR T-cell therapy for the same.
“Amongst End-Users, hospitals segment holds the major share”
Based on end-users, the market is fragmented into hospitals, cancer treatments centers, and others. In 2020, hospitals segment grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period owing to the increasing number of hospitals in various emerging economies, better infrastructure & accessibility of various healthcare services at hospitals leading to the growing preference of patients for treatment in the hospital settings. However, cancer treatments centers are also likely to witness the fastest growth during the forecast period.
“North America represents one of the largest markets of CAR T-cell therapy market”
For a better understanding of the market dynamics of the CAR T-cell therapy market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America constitutes a major market for the CAR T-cell therapy market industry and generated revenue of USD XX Million in 2020 owing to strong healthcare infrastructure and growing adoption of CAR T-cell therapy in the region.
Reasons to buy this report:
Customization Options:
The global CAR T-cell therapy market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Covid-19 Impact
6. Global Car T-cell Therapy Market Revenue
7. Market Insights By Product
8. Market Insights By Indication
9. Market Insights By End-users
10. Market Insights By Region
11. Car T-cell Therapy Market Dynamics
12. Car T-cell Therapy Market Opportunities
13. Car T-cell Therapy Market Trends & Insights
14. Legal & Regulatory Framework
15. Demand And Supply Side Analysis
16. Value Chain Analysis
17. Competitive Scenario
18. Company Profiled
19. Disclaimer
Analyzing the historical market, estimation of the current market, and forecasting the future market of the global CAR T-cell therapy market were the three major steps undertaken to create and analyze the adoption of CAR T-cell therapy in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global CAR T-cell therapy market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments the industry pertains to. Detailed methodology is explained below:
Seek More Details About Research Methodology
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the CAR T-cell therapy through company internal sources such as annual report & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the CAR T-cell therapy market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments included in the report as product, indication, and end-users. Further country-level analyses were conducted to evaluate the overall adoption of CAR T-cell therapy across the globe.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the CAR T-cell therapy. Further, we conducted factor analysis using dependent and independent variables such as growing advancement in technology and increasing prevalence of cancer. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, merger and acquisition, business expansion, and product launches in the CAR T-cell therapy sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the CAR T-cell therapy market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., top-down/bottom-up approach was applied to arrive at the market forecast about 2027 for different segments and subsegments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, and Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
Data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers of each segment and sub-segment of the CAR T-cell therapy market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of product, indication, and end-users of the CAR T-cell therapy market.
The main objective of the CAR T-Cell Therapy Market Study
The current & future market trends of CAR T-cell therapy were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future market trends were determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit as a first-mover advantage. Other quantitative goals of the studies include:
Deep dive regional level analysis of the industry
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
